Savara (NASDAQ:SVRA) had its price objective trimmed by Canaccord Genuity from $22.00 to $15.00 in a research note published on Thursday morning, The Fly reports. The brokerage currently has a buy rating on the stock.
Other analysts also recently issued reports about the company. LADENBURG THALM/SH SH reaffirmed a buy rating and set a $21.00 price objective on shares of Savara in a research note on Monday, April 1st. Zacks Investment Research raised Savara from a hold rating to a buy rating and set a $10.00 price objective for the company in a research note on Thursday, April 11th. BidaskClub raised Savara from a hold rating to a buy rating in a research note on Friday, April 5th. HC Wainwright reduced their price objective on Savara from $22.00 to $6.00 and set a buy rating for the company in a research note on Thursday. Finally, Roth Capital set a $10.00 price objective on Savara and gave the company a hold rating in a research note on Tuesday, May 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of Hold and a consensus target price of $8.10.
Shares of NASDAQ SVRA traded up $0.02 during trading hours on Thursday, reaching $2.62. The stock had a trading volume of 7,954 shares, compared to its average volume of 311,851. The company has a quick ratio of 12.05, a current ratio of 12.05 and a debt-to-equity ratio of 0.24. The stock has a market cap of $378.73 million, a PE ratio of -2.04 and a beta of 0.95. Savara has a fifty-two week low of $2.55 and a fifty-two week high of $14.06.
Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.05. Sell-side analysts anticipate that Savara will post -1.63 earnings per share for the current year.
In other news, insider Jaakko Taneli Jouhikainen sold 25,000 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $9.03, for a total transaction of $225,750.00. Following the completion of the transaction, the insider now directly owns 184,754 shares of the company’s stock, valued at approximately $1,668,328.62. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO David L. Lowrance sold 7,500 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $9.02, for a total value of $67,650.00. Following the transaction, the chief financial officer now directly owns 2,446 shares of the company’s stock, valued at $22,062.92. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 75,261 shares of company stock valued at $744,174. 6.50% of the stock is owned by company insiders.
Hedge funds have recently modified their holdings of the company. Citigroup Inc. grew its stake in Savara by 23.1% in the first quarter. Citigroup Inc. now owns 8,377 shares of the company’s stock worth $62,000 after purchasing an additional 1,570 shares in the last quarter. Metropolitan Life Insurance Co NY acquired a new position in shares of Savara during the first quarter worth approximately $83,000. The Manufacturers Life Insurance Company raised its holdings in Savara by 12.5% during the first quarter. The Manufacturers Life Insurance Company now owns 11,550 shares of the company’s stock worth $85,000 after purchasing an additional 1,279 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Savara in the fourth quarter valued at $93,000. Finally, DekaBank Deutsche Girozentrale increased its holdings in shares of Savara by 19.4% in the first quarter. DekaBank Deutsche Girozentrale now owns 12,300 shares of the company’s stock valued at $141,000 after buying an additional 2,000 shares in the last quarter. 45.71% of the stock is owned by institutional investors and hedge funds.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Article: Dollar Cost Averaging
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.